The DOI matches its Crossref record; 202 of the 202 references it cites were found in a registry or an index.
CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases
Open accessAbstract
At present, the idea of genome modification has revolutionized the modern therapeutic research era. Genome modification studies have traveled a long way from gene modifications in primary cells to genetic modifications in animals. The targeted genetic modification may result in the modulation (i.e., either upregulation or downregulation) of the predefined gene expression. Clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated nuclease 9 (Cas9) is a promising genome-editing tool that has therapeutic potential against incurable genetic disorders by modifying their DNA sequences. In comparison with other genome-editing techniques, CRISPR-Cas9 is simple, efficient, and very specific. This enabled CRISPR-Cas9 genome-editing technology to enter into clinical trials against cancer. Besides therapeutic potential, the CRISPR-Cas9 tool can also be applied to generate genetically inhibited animal models for drug discovery and development. This comprehensive review paper discusses the origin of CRISPR-Cas9 systems and their therapeutic potential against various genetic disorders, including cancer, allergy, immunological disorders, Duchenne muscular dystrophy, cardiovascular disorders, neurological disorders, liver-related disorders, cystic fibrosis, blood-related disorders, eye-related disorders, and viral infection. Finally, we discuss the different challenges, safety concerns, and strategies that can be applied to overcome the obstacles during CRISPR-Cas9-mediated therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Unexpected mutations after CRISPR–Cas9 editing in vivo
Schaefer, K. A., Wu, W.-H., Colgan, D. F., Tsang, S. H., Bassuk, A. G., & Mahajan, V. B. (2017) · Nature Methods · doi:10.1038/nmeth.4293 · Cited by 286
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016) · Nature · doi:10.1038/nature17946 · Cited by 5,437
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292 · cited 1×
“It was observed that off-target effects were common in human cell culture with persistent Cas9 expression.(187,188) while these effects were less common in in vivomodels.”
BackgroundLong-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Small CRISPR RNAs Guide Antiviral Defense in Prokaryotes
Brouns, S. J. J., Jore, M. M., Lundgren, M., Westra, E. R., Slijkhuis, R. J. H., Snijders, A. P. L., Dickman, M. J., Makarova, K. S., Koonin, E. V., & van der Oost, J. (2008) · Science · doi:10.1126/science.1159689 · Cited by 2,460
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., Dahlman, J. E., Parnas, O., Eisenhaure, T. M., Jovanovic, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.014 · Cited by 2,001
Targeting DNA Double-Strand Breaks with TAL Effector Nucleases
Christian, M., Cermak, T., Doyle, E. L., Schmidt, C., Zhang, F., Hummel, A., Bogdanove, A. J., & Voytas, D. F. (2010) · Genetics · doi:10.1534/genetics.110.120717 · Cited by 1,869
Identification of genes that are associated with DNA repeats in prokaryotes
Jansen, R., Embden, J. D. A. V., Gaastra, W., & Schouls, L. M. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.02839.x · Cited by 1,802
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
TALENs: A widely applicable technology for targeted genome editing
Joung, J. K., & Sander, J. D. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3486 · Cited by 1,650 · cited 2×
“TALENs have a benefit over ZFNs, as they can recognize a single nucleotide and are more specific than ZFNs.35 Still, packaging and delivery of TALENs might be a challenge because they have a large size than ZFNs.23 CRISPR-Cas9 is latest gene-editing technique with various advantages over ZFNs and TALENs.”
BackgroundCRISPR-engineered T cells in patients with refractory cancer
Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science · doi:10.1126/science.aba7365 · Cited by 1,478
Galanello, R., & Origa, R. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-11 · Cited by 1,466
Schwank, G., Koo, B.-K., Sasselli, V., Dekkers, J. F., Heo, I., Demircan, T., Sasaki, N., Boymans, S., Cuppen, E., van der Ent, C. K., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.11.002 · Cited by 1,424 · cited 2×
“In primary adult stem cells, CFTR gene alteration was done through homologous recombination.(57) Therefore, CRISPR technology might be a potential approach for the treatment of CF in future.”
BackgroundMethodAnalysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases
Cho, S. W., Kim, S., Kim, Y., Kweon, J., Kim, H. S., Bae, S., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.162339.113 · Cited by 1,356
Chu, V. T., Weber, T., Wefers, B., Wurst, W., Sander, S., Rajewsky, K., & Kühn, R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3198 · Cited by 1,210
The CRISPR/Cas9 system for plant genome editing and beyond
Bortesi, L., & Fischer, R. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.12.006 · Cited by 1,187
Delivering CRISPR: a review of the challenges and approaches
Lino, C. A., Harper, J. C., Carney, J. P., & Timlin, J. A. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1474964 · Cited by 1,185
In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration
Suzuki, K., Tsunekawa, Y., Hernandez-Benitez, R., Wu, J., Zhu, J., Kim, E. J., Hatanaka, F., Yamamoto, M., Araoka, T., Li, Z., et al. (2016) · Nature · doi:10.1038/nature20565 · Cited by 1,150
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
Nelson, C. E., Hakim, C. H., Ousterout, D. G., Thakore, P. I., Moreb, E. A., Rivera, R. M. C., Madhavan, S., Pan, X., Ran, F. A., Yan, W. X., et al. (2016) · Science · doi:10.1126/science.aad5143 · Cited by 1,144
Maruyama, T., Dougan, S. K., Truttmann, M. C., Bilate, A. M., Ingram, J. R., & Ploegh, H. L. (2015) · Nature Biotechnology · doi:10.1038/nbt.3190 · Cited by 1,137
Modeling colorectal cancer using CRISPR-Cas9–mediated engineering of human intestinal organoids
Matano, M., Date, S., Shimokawa, M., Takano, A., Fujii, M., Ohta, Y., Watanabe, T., Kanai, T., & Sato, T. (2015) · Nature Medicine · doi:10.1038/nm.3802 · Cited by 1,135 · cited 1×
“CRISPR-Cas9 technology was also used to initiate multiple gene mutations to develop human colonic epithelium in the colorectal cancer model.(80) CRISPR-Cas9-mediated knockout of single gene, i.”
MethodDNA Recognition by Cys2His2 Zinc Finger Proteins
Wolfe, S. A., Nekludova, L., & Pabo, C. O. (2000) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.29.1.183 · Cited by 1,053
In vivo gene editing in dystrophic mouse muscle and muscle stem cells
Tabebordbar, M., Zhu, K., Cheng, J. K. W., Chew, W. L., Widrick, J. J., Yan, W. X., Maesner, C., Wu, E. Y., Xiao, R., Ran, F. A., et al. (2016) · Science · doi:10.1126/science.aad5177 · Cited by 1,046
Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing
Tsai, S. Q., Wyvekens, N., Khayter, C., Foden, J. A., Thapar, V., Reyon, D., Goodwin, M. J., Aryee, M. J., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2908 · Cited by 952
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype
Yin, H., Xue, W., Chen, S., Bogorad, R. L., Benedetti, E., Grompe, M., Koteliansky, V., Sharp, P. A., Jacks, T., & Anderson, D. G. (2014) · Nature Biotechnology · doi:10.1038/nbt.2884 · Cited by 951
Saudou, F., & Humbert, S. (2016) · Neuron · doi:10.1016/j.neuron.2016.02.003 · Cited by 951
Long, C., Amoasii, L., Mireault, A. A., McAnally, J. R., Li, H., Sanchez-Ortiz, E., Bhattacharyya, S., Shelton, J. M., Bassel-Duby, R., & Olson, E. N. (2016) · Science · doi:10.1126/science.aad5725 · Cited by 937
Heritable genome editing in C. elegans via a CRISPR-Cas9 system
Friedland, A. E., Tzur, Y. B., Esvelt, K. M., Colaiácovo, M. P., Church, G. M., & Calarco, J. A. (2013) · Nature Methods · doi:10.1038/nmeth.2532 · Cited by 899
Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis
Chen, S., Sanjana, N. E., Zheng, K., Shalem, O., Lee, K., Shi, X., Scott, D. A., Song, J., Pan, J. Q., Weissleder, R., et al. (2015) · Cell · doi:10.1016/j.cell.2015.02.038 · Cited by 862
Rapoport, A. P., Stadtmauer, E. A., Binder-Scholl, G. K., Goloubeva, O., Vogl, D. T., Lacey, S. F., Badros, A. Z., Garfall, A., Weiss, B., Finklestein, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3910 · Cited by 856
Enhancing Gene Targeting with Designed Zinc Finger Nucleases
Bibikova, M., Beumer, K., Trautman, J. K., & Carroll, D. (2003) · Science · doi:10.1126/science.1079512 · Cited by 823
A Familial Alzheimer's Disease Locus on Chromosome 1
Levy-Lahad, E., Wijsman, E. M., Nemens, E., Anderson, L., Goddard, K. A. B., Weber, J. L., Bird, T. D., & Schellenberg, G. D. (1995) · Science · doi:10.1126/science.7638621 · Cited by 813
Gene Therapy Death Prompts Review of Adenovirus Vector
Marshall, E. (1999) · Science · doi:10.1126/science.286.5448.2244 · Cited by 760
Lee, K., Conboy, M., Park, H. M., Jiang, F., Kim, H. J., Dewitt, M. A., Mackley, V. A., Chang, K., Rao, A., Skinner, C., et al. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0137-2 · Cited by 755
Cao, A., & Galanello, R. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181cd68ed · Cited by 722
Prevention of muscular dystrophy in mice by CRISPR/Cas9–mediated editing of germline DNA
Long, C., McAnally, J. R., Shelton, J. M., Mireault, A. A., Bassel-Duby, R., & Olson, E. N. (2014) · Science · doi:10.1126/science.1254445 · Cited by 720
Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice
Simpson, E. M., Linder, C. C., Sargent, E. E., Davisson, M. T., Mobraaten, L. E., & Sharp, J. J. (1997) · Nature Genetics · doi:10.1038/ng0597-19 · Cited by 686
Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
Alfarouk, K. O., Stock, C.-M., Taylor, S., Walsh, M., Muddathir, A. K., Verduzco, D., Bashir, A. H. H., Mohammed, O. Y., Elhassan, G. O., Harguindey, S., et al. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0221-1 · Cited by 665
Efficacy of Gene Therapy for X-Linked Severe Combined Immunodeficiency
Hacein-Bey-Abina, S., Hauer, J., Lim, A., Picard, C., Wang, G. P., Berry, C. C., Martinache, C., Rieux-Laucat, F., Latour, S., Belohradsky, B. H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000164 · Cited by 639
Self‐assembled DNA nanoclews for the efficient delivery of CRISPR–Cas9 for genome editing
Sun, W., Ji, W., Hall, J. M., Hu, Q., Wang, C., Beisel, C. L., & Gu, Z. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506030 · Cited by 629
Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles
Wang, M., Zuris, J. A., Meng, F., Rees, H., Sun, S., Deng, P., Han, Y., Gao, X., Pouli, D., Wu, Q., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520244113 · Cited by 624
How the Fanconi Anemia Pathway Guards the Genome
Moldovan, G.-L., & D'Andrea, A. D. (2009) · Annual Review of Genetics · doi:10.1146/annurev-genet-102108-134222 · Cited by 590
Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus
Ebina, H., Misawa, N., Kanemura, Y., & Koyanagi, Y. (2013) · Scientific Reports · doi:10.1038/srep02510 · Cited by 565 · cited 1×
“It was observed that CRISPR-Cas9 can mutate LTRs in the DNA of HIV-1 provirus, leading to the breakdown of latent HIV-1 provirus.(60) In a negative feedback regulation of HIV-1, the Cas9 gene was placed under the control of a minimal HIV-1 promoter to express Cas9 in HIV-1 contagious cells.”
BackgroundA dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice
Yang, Y., Wang, L., Bell, P., McMenamin, D., He, Z., White, J., Yu, H., Xu, C., Morizono, H., Musunuru, K., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3469 · Cited by 556 · cited 2×
“Yang et al.(119) worked on CRISPR-Cas9-mediated gene editing-based correction of X-linked deficiency in OTC to treat urea cycle disorder in an infant mice model.”
BackgroundHeckl, D., Kowalczyk, M. S., Yudovich, D., Belizaire, R., Puram, R. V., McConkey, M. E., Thielke, A., Aster, J. C., Regev, A., & Ebert, B. L. (2014) · Nature Biotechnology · doi:10.1038/nbt.2951 · Cited by 555
Lu, Y., Xue, J., Deng, T., Zhou, X., Yu, K., Deng, L., Huang, M., Yi, X., Liang, M., Wang, Y., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0840-5 · Cited by 539
Classification and evolution of type II CRISPR-Cas systems
Chylinski, K., Makarova, K. S., Charpentier, E., & Koonin, E. V. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku241 · Cited by 498
Ousterout, D. G., Kabadi, A. M., Thakore, P. I., Majoros, W. H., Reddy, T. E., & Gersbach, C. A. (2015) · Nature Communications · doi:10.1038/ncomms7244 · Cited by 470
CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
Wang, Y., Zhang, T., Kwiatkowski, N., Abraham, B. J., Lee, T. I., Xie, S., Yuzugullu, H., Von, T., Li, H., Lin, Z., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.063 · Cited by 465
CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia
Xu, L., Wang, J., Liu, Y., Xie, L., Su, B., Mou, D., Wang, L., Liu, T., Wang, X., Zhang, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817426 · Cited by 454
A CRISPR/Cas system mediates bacterial innate immune evasion and virulence
Sampson, T. R., Saroj, S. D., Llewellyn, A. C., Tzeng, Y.-L., & Weiss, D. S. (2013) · Nature · doi:10.1038/nature12048 · Cited by 443
Wang, X., Wang, Y., Wu, X., Wang, J., Wang, Y., Qiu, Z., Chang, T., Huang, H., Lin, R.-J., & Yee, J.-K. (2015) · Nature Biotechnology · doi:10.1038/nbt.3127 · Cited by 442 · cited 1×
“It was observed that off-target effects were common in human cell culture with persistent Cas9 expression.(187,188) while these effects were less common in in vivomodels.”
BackgroundTreatment of a metabolic liver disease by in vivo genome base editing in adult mice
Villiger, L., Grisch-Chan, H. M., Lindsay, H., Ringnalda, F., Pogliano, C. B., Allegri, G., Fingerhut, R., Häberle, J., Matos, J., Robinson, M. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0209-1 · Cited by 429
Wang, P., Zhang, L., Zheng, W., Cong, L., Guo, Z., Xie, Y., Wang, L., Tang, R., Feng, Q., Hamada, Y., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201708689 · Cited by 410
Xie, F., Ye, L., Chang, J. C., Beyer, A. I., Wang, J., Muench, M. O., & Kan, Y. W. (2014) · Genome Research · doi:10.1101/gr.173427.114 · Cited by 408
Applications of the CRISPR-Cas9 system in cancer biology
Sánchez-Rivera, F. J., & Jacks, T. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3950 · Cited by 405
Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures
Doyon, Y., Vo, T. D., Mendel, M. C., Greenberg, S. G., Wang, J., Xia, D. F., Miller, J. C., Urnov, F. D., Gregory, P. D., & Holmes, M. C. (2011) · Nature Methods · doi:10.1038/nmeth.1539 · Cited by 402
Aubrey, B. J., Kelly, G. L., Kueh, A. J., Brennan, M. S., O’Connor, L., Milla, L., Wilcox, S., Tai, L., Strasser, A., & Herold, M. J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.002 · Cited by 399
CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease
Yang, S., Chang, R., Yang, H., Zhao, T., Hong, Y., Kong, H. E., Sun, X., Qin, Z., Jin, P., Li, S., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92087 · Cited by 399
The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo
Lin, S.-R., Yang, H.-C., Kuo, Y.-T., Liu, C.-J., Yang, T.-Y., Sung, K.-C., Lin, Y.-Y., Wang, H.-Y., Wang, C.-C., Shen, Y.-C., et al. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.38 · Cited by 386
A guide to manufacturing CAR T cell therapies
Vormittag, P., Gunn, R., Ghorashian, S., & Veraitch, F. S. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.01.025 · Cited by 383
Unexpected failure rates for modular assembly of engineered zinc fingers
Ramirez, C. L., Foley, J. E., Wright, D. A., Müller-Lerch, F., Rahman, S. H., Cornu, T. I., Winfrey, R. J., Sander, J. D., Fu, F., Townsend, J. A., et al. (2008) · Nature Methods · doi:10.1038/nmeth0508-374 · Cited by 378
CRISPR gene-editing tested in a person for the first time
Cyranoski, D. (2016) · Nature · doi:10.1038/nature.2016.20988 · Cited by 362
CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo
Monteys, A. M., Ebanks, S. A., Keiser, M. S., & Davidson, B. L. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.11.010 · Cited by 309
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
Su, S., Hu, B., Shao, J., Shen, B., Du, J., Du, Y., Zhou, J., Yu, L., Zhang, L., Chen, F., et al. (2016) · Scientific Reports · doi:10.1038/srep20070 · Cited by 305
CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus
Ramanan, V., Shlomai, A., Cox, D. B. T., Schwartz, R. E., Michailidis, E., Bhatta, A., Scott, D. A., Zhang, F., Rice, C. M., & Bhatia, S. N. (2015) · Scientific Reports · doi:10.1038/srep10833 · Cited by 304
Bakondi, B., Lv, W., Lu, B., Jones, M. K., Tsai, Y., Kim, K. J., Levy, R., Akhtar, A. A., Breunig, J. J., Svendsen, C. N., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2015.220 · Cited by 296
A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo
Jiang, C., Mei, M., Li, B., Zhu, X., Zu, W., Tian, Y., Wang, Q., Guo, Y., Dong, Y., & Tan, X. (2017) · Cell Research · doi:10.1038/cr.2017.16 · Cited by 295
Pennisi, E. (2013) · Science · doi:10.1126/science.341.6148.833 · Cited by 287
Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling
Zuckermann, M., Hovestadt, V., Knobbe-Thomsen, C. B., Zapatka, M., Northcott, P. A., Schramm, K., Belic, J., Jones, D. T. W., Tschida, B., Moriarity, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms8391 · Cited by 283
Using the mouse to model human disease: increasing validity and reproducibility
Justice, M. J., & Dhillon, P. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.024547 · Cited by 281
Viral Delivery Systems for CRISPR
Xu, C. L., Ruan, M. Z. C., Mahajan, V. B., & Tsang, S. H. (2019) · Viruses · doi:10.3390/v11010028 · Cited by 277 · cited 1×
“AAVs and LVs are the most commonly used viral vectors for gene editing.(202) The advantages of AAVs includes a less immunogenic property, serotype specificity, a good safety profile, and the ability to transduce both dividing and non-dividing cells.”
BackgroundPermanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9
Shin, J. W., Kim, K.-H., Chao, M. J., Atwal, R. S., Gillis, T., MacDonald, M. E., Gusella, J. F., & Lee, J.-M. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw286 · Cited by 276
Craig, R. (2002) · Leukemia · doi:10.1038/sj.leu.2402416 · Cited by 266
Kennedy, E. M., Kornepati, A. V. R., Goldstein, M., Bogerd, H. P., Poling, B. C., Whisnant, A. W., Kastan, M. B., & Cullen, B. R. (2014) · Journal of Virology · doi:10.1128/jvi.01879-14 · Cited by 262
Update on the Kelch-like (KLHL) gene family
Dhanoa, B. S., Cogliati, T., Satish, A. G., Bruford, E. A., & Friedman, J. S. (2013) · Human Genomics · doi:10.1186/1479-7364-7-13 · Cited by 258
CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells
Min, Y.-L., Li, H., Rodriguez-Caycedo, C., Mireault, A. A., Huang, J., Shelton, J. M., McAnally, J. R., Amoasii, L., Mammen, P. P. A., Bassel-Duby, R., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav4324 · Cited by 251
Cas9-mediated targeting of viral RNA in eukaryotic cells
Price, A. A., Sampson, T. R., Ratner, H. K., Grakoui, A., & Weiss, D. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1422340112 · Cited by 250
Biology of human papillomaviruses
Mcmurray, H. R., Nguyen, D., Westbrook, T. F., & Mcance, D. J. (2001) · International Journal of Experimental Pathology · doi:10.1046/j.1365-2613.2001.00177.x · Cited by 248
Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication
Dong, C., Qu, L., Wang, H., Wei, L., Dong, Y., & Xiong, S. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.03.015 · Cited by 244
CRISPR–Cas9 genome editing in human cells occurs via the Fanconi anemia pathway
Richardson, C. D., Kazane, K. R., Feng, S. J., Zelin, E., Bray, N. L., Schäfer, A. J., Floor, S. N., & Corn, J. E. (2018) · Nature Genetics · doi:10.1038/s41588-018-0174-0 · Cited by 242
Check, E. (2002) · Nature · doi:10.1038/420116a · Cited by 238
Gaspar, H. B., Cooray, S., Gilmour, K. C., Parsley, K. L., Adams, S., Howe, S. J., Al Ghonaium, A., Bayford, J., Brown, L., Davies, E. G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002715 · Cited by 232
A New Class of Medicines through DNA Editing
Porteus, M. H. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1800729 · Cited by 229 · cited 2×
“The highlights of CRISPR-Cas9 technology involve its ability to treat various human diseases via genome editing (Figure 2).(15) Accumulating evidence suggests successful genome editing in mammalian cells via CRISPR-Cas9 technology.”
BackgroundDiagnostic Evaluation of Mononucleosis-Like Illnesses
Hurt, C., & Tammaro, D. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.12.011 · Cited by 227
CRISPR‐Cas9 Genome Editing in Drosophila
Gratz, S. J., Rubinstein, C. D., Harrison, M. M., Wildonger, J., & O'Connor‐Giles, K. M. (2015) · Current Protocols in Molecular Biology · doi:10.1002/0471142727.mb3102s111 · Cited by 224
Liu, Y., Zeng, Y., Liu, L., Zhuang, C., Fu, X., Huang, W., & Cai, Z. (2014) · Nature Communications · doi:10.1038/ncomms6393 · Cited by 223 · cited 2×
“It has been proposed that the mutated oncogenes and tumor suppressor genes in cancer cells might function as smart therapeutic targets, suggesting that the modulation of tumor suppressor genes can induce apoptosis in tumor cells.67,68 Liu et al.69 observed the effective inhibition of bladder cancer cell proliferation,…”
BackgroundCRISPR RNAs Trigger Innate Immune Responses in Human Cells
Kim, S., Koo, T., Jee, H.-G., Cho, H.-Y., Lee, G., Lim, D.-G., Shin, H. S., & Kim, J.-S. (2018) · Genome Research · doi:10.1101/gr.231936.117 · Cited by 222
CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells
Hoban, M. D., Lumaquin, D., Kuo, C. Y., Romero, Z., Long, J., Ho, M., Young, C. S., Mojadidi, M., Fitz-Gibbon, S., Cooper, A. R., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.148 · Cited by 220
Kogure, K., Moriguchi, R., Sasaki, K., Ueno, M., Futaki, S., & Harashima, H. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.04.024 · Cited by 218
Deletions, Inversions, Duplications: Engineering of Structural Variants using CRISPR/Cas in Mice
Kraft, K., Geuer, S., Will, A. J., Chan, W. L., Paliou, C., Borschiwer, M., Harabula, I., Wittler, L., Franke, M., Ibrahim, D. M., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.01.016 · Cited by 216
Potential pitfalls of CRISPR/Cas9‐mediated genome editing
Peng, R., Lin, G., & Li, J. (2016) · The FEBS Journal · doi:10.1111/febs.13586 · Cited by 213
Ephrin receptor A2 is a functional entry receptor for Epstein–Barr virus
Chen, J., Sathiyamoorthy, K., Zhang, X., Schaller, S., Perez White, B. E., Jardetzky, T. S., & Longnecker, R. (2018) · Nature Microbiology · doi:10.1038/s41564-017-0081-7 · Cited by 210
Sickle Cell Anemia and Its Phenotypes
Williams, T., & Thein, S. L. (2018) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083117-021320 · Cited by 200
Yang, H., Wu, J.-J., Tang, T., Liu, K.-D., & Dai, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-07871-9 · Cited by 199
Crane, A. M., Kramer, P., Bui, J. H., Chung, W. J., Li, X. S., Gonzalez-Garay, M. L., Hawkins, F., Liao, W., Mora, D., Choi, S., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.02.005 · Cited by 193
Ye, L., Wang, J., Tan, Y., Beyer, A. I., Xie, F., Muench, M. O., & Kan, Y. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612075113 · Cited by 190
György, B., Lööv, C., Zaborowski, M. P., Takeda, S., Kleinstiver, B. P., Commins, C., Kastanenka, K., Mu, D., Volak, A., Giedraitis, V., et al. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.03.007 · Cited by 190
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
Fousek, K., Watanabe, J., Joseph, S. K., George, A., An, X., Byrd, T. T., Morris, J. S., Luong, A., Martínez-Paniagua, M. A., Sanber, K., et al. (2021) · Leukemia · doi:10.1038/s41375-020-0792-2 · Cited by 182
Improved delivery of Cas9 protein/gRNA complexes using lipofectamine CRISPRMAX
Yu, X., Liang, X., Xie, H., Kumar, S., Ravinder, N., Potter, J., de Mollerat du Jeu, X., & Chesnut, J. D. (2016) · Biotechnology Letters · doi:10.1007/s10529-016-2064-9 · Cited by 176
Review and update: Current treatment trends for patients with retinitis pigmentosa
Shintani, K., Shechtman, D. L., & Gurwood, A. S. (2009) · Optometry - Journal of the American Optometric Association · doi:10.1016/j.optm.2008.01.026 · Cited by 175
Bergeron, N., Phan, B. A. P., Ding, Y., Fong, A., & Krauss, R. M. (2015) · Circulation · doi:10.1161/circulationaha.115.016080 · Cited by 171
CRISPR/Cas9-mediated genome editing of Epstein–Barr virus in human cells
Yuen, K.-S., Chan, C.-P., Wong, N.-H. M., Ho, C.-H., Ho, T.-H., Lei, T., Deng, W., Tsao, S. W., Chen, H., Kok, K.-H., et al. (2015) · Journal of General Virology · doi:10.1099/jgv.0.000012 · Cited by 168
Lau, C.-H., & Suh, Y. (2017) · F1000Research · doi:10.12688/f1000research.11243.1 · Cited by 161
Zhang, Y., Li, H., Min, Y.-L., Sanchez-Ortiz, E., Huang, J., Mireault, A. A., Shelton, J. M., Kim, J., Mammen, P. P. A., Bassel-Duby, R., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay6812 · Cited by 161
Chinese scientists to pioneer first human CRISPR trial
Cyranoski, D. (2016) · Nature · doi:10.1038/nature.2016.20302 · Cited by 160
Severe muscular dystrophy in mice that lack dystrophin and α7 integrin
Rooney, J. E., Welser, J. V., Dechert, M. A., Flintoff‐Dye, N. L., Kaufman, S. J., & Burkin, D. J. (2006) · Journal of Cell Science · doi:10.1242/jcs.02952 · Cited by 155
CRISPR/Cas9 Screens Reveal Epstein-Barr Virus-Transformed B Cell Host Dependency Factors
Ma, Y., Walsh, M. J., Bernhardt, K., Ashbaugh, C. W., Trudeau, S. J., Ashbaugh, I. Y., Jiang, S., Jiang, C., Zhao, B., Root, D. E., et al. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.04.005 · Cited by 149
van Agtmaal, E. L., André, L. M., Willemse, M. P., Cumming, S. A., van Kessel, I. D. G., van den Broek, W. J. A. A., Gourdon, G., Furling, D., Mouly, V., Monckton, D. G., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.014 · Cited by 147
Bhattacharya, D., Marfo, C. A., Li, D., Lane, M., & Khokha, M. K. (2015) · Developmental Biology · doi:10.1016/j.ydbio.2015.11.003 · Cited by 143
Myeloid malignancies: mutations, models and management
Murati, A., Brecqueville, M., Devillier, R., Mozziconacci, M.-J., Gelsi-Boyer, V., & Birnbaum, D. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-304 · Cited by 139
No unexpected CRISPR-Cas9 off-target activity revealed by trio sequencing of gene-edited mice
Iyer, V., Boroviak, K., Thomas, M., Doe, B., Riva, L., Ryder, E., & Adams, D. J. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007503 · Cited by 138
A sheep model of cystic fibrosis generated by CRISPR/Cas9 disruption of the CFTR gene
Fan, Z., Périssé, I. V., Cotton, C. U., Regouski, M., Meng, Q., Domb, C., Wettere, A. J. V., Wang, Z., Harris, A., White, K. L., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.123529 · Cited by 135
Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing
Han, H. A., Pang, J. K. S., & Soh, B.-S. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01893-z · Cited by 134
In vivo genome editing via the HITI method as a tool for gene therapy
Suzuki, K., & Belmonte, J. C. I. (2017) · Journal of Human Genetics · doi:10.1038/s10038-017-0352-4 · Cited by 131
Hultquist, J. F., Hiatt, J. B., Schumann, K., McGregor, M., Roth, T. L., Haas, P., Doudna, J. A., Marson, A., & Krogan, N. J. (2018) · Nature Protocols · doi:10.1038/s41596-018-0069-7 · Cited by 131
Fanconi Anemia Gene Editing by the CRISPR/Cas9 System
Osborn, M. J., Gabriel, R., Webber, B. R., DeFeo, A. P., McElroy, A. N., Jarjour, J., Starker, C. G., Wagner, J. E., Joung, J. K., Voytas, D. F., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.111 · Cited by 130
CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X
Karimova, M., Beschorner, N., Dammermann, W., Chemnitz, J., Indenbirken, D., Bockmann, J., Grundhoff, A. T., Lüth, S., Buchholz, F., Wiesch, J. S. Z., et al. (2015) · Scientific Reports · doi:10.1038/srep13734 · Cited by 130
CRISPR/Cas9‑mediated cervical cancer treatment targeting human papillomavirus E6
Yoshiba, T., Saga, Y., Urabe, M., Uchibor, R., Matsubara, S., Fujiwara, H., & Mizukami, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.9815 · Cited by 128
Chang, C., Lai, Y.-S., Westin, E. R., Khodadadi‐Jamayran, A., Pawlik, K. M., Lamb, L. S., Goldman, F. D., & Townes, T. M. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.013 · Cited by 123
Human papillomavirus molecular biology and pathogenesis
Sanclemente, G., & Gill, D. (2002) · Journal of the European Academy of Dermatology and Venereology · doi:10.1046/j.1473-2165.2002.00419.x · Cited by 123
HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells
Hartweger, H., McGuire, A. T., Horning, M., Taylor, J. J., Dosenovic, P., Yost, D., Gazumyan, A., Seaman, M. S., Stamatatos, L., Janković, M., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190287 · Cited by 123
CRISPR treatment inserted directly into the body for first time
Ledford, H. (2020) · Nature · doi:10.1038/d41586-020-00655-8 · Cited by 119
Primary Immunodeficiency and Autoimmunity: Lessons From Human Diseases
Arason, G. J., Jörgensen, G. H., & Ludviksson, B. R. (2010) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2010.02386.x · Cited by 118
Guo, C., Willem, M., Werner, A., Raivich, G., Emerson, M., Neyses, L., & Mayer, U. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl018 · Cited by 114
Targeting Cdk11 in osteosarcoma cells using the CRISPR‐cas9 system
Feng, Y., Sassi, S. O., Shen, J. K., Yang, X., Gao, Y., Osaka, E., Zhang, J., Yang, S., Cao, Y., Mankin, H. J., et al. (2014) · Journal of Orthopaedic Research® · doi:10.1002/jor.22745 · Cited by 113
CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges
Yi, L., & Li, J. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.09.002 · Cited by 112
Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy
Li, H., Huang, M., Jiang, J., & Peng, Z. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i47.5297 · Cited by 112
CRISPR/Cas9 in zebrafish: an efficient combination for human genetic diseases modeling
Liu, J., Zhou, Y., Qi, X., Chen, J., Chen, W., Qiu, G., Wu, Z., & Wu, N. (2016) · Human Genetics · doi:10.1007/s00439-016-1739-6 · Cited by 110
Chu, H. W., Rios, C. L., Huang, C.-J., Wesolowska‐Andersen, A., Burchard, E. G., O’Connor, B. P., Fingerlin, T. E., Nichols, D. P., Reynolds, S. D., & Seibold, M. A. (2015) · Gene Therapy · doi:10.1038/gt.2015.53 · Cited by 109
Niu, Y., Xu, J., & Sun, T. (2019) · Journal of Cancer · doi:10.7150/jca.32628 · Cited by 109
Gene mutations in retinitis pigmentosa and their clinical implications
Wang, D., Chan, W., Tam, P. O. S., Baum, L., Lam, D. S. C., Chong, K. K. L., Fan, B., & Pang, C. P. (2004) · Clinica Chimica Acta · doi:10.1016/j.cccn.2004.08.004 · Cited by 103
Chemokine receptor 5 knockout strategies
Cannon, P. M., & June, C. H. (2010) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32834122d7 · Cited by 101
Seeking the Cause of Induced Leukemias in X-SCID Trial
Kaiser, J. (2003) · Science · doi:10.1126/science.299.5606.495 · Cited by 101
First-in-human Phase 1 CRISPR Gene Editing Cancer Trials: Are We Ready?
Baylis, F. E., & McLeod, M. (2017) · Current Gene Therapy · doi:10.2174/1566523217666171121165935 · Cited by 98
Tessadori, F., Roessler, H. I., Savelberg, S. M. C., Chocron, S., Kamel, S. M., Duran, K. J., van Haelst, M. M., van Haaften, G. W., & Bakkers, J. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.035469 · Cited by 98
Liu, T., Li, Z., Zhang, Q., Bernstein, K. D. A., Lozano‐Calderón, S. A., Choy, E., Hornicek, F. J., & Duan, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.13148 · Cited by 96
Inhibition of nonhomologous end joining to increase the specificity of CRISPR/Cas9 genome editing
Vartak, S. V., & Raghavan, S. C. (2015) · The FEBS Journal · doi:10.1111/febs.13416 · Cited by 92
Valletta, S., Dolatshad, H., Bartenstein, M., Yip, B. H., Bello, E., Gordon, S. A. K., Yu, Y., Shaw, J. M., Roy, S., Scifo, L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6392 · Cited by 90
Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?
Seimetz, D., Heller, K., & Richter, J. (2019) · Cell Medicine · doi:10.1177/2155179018822781 · Cited by 90
A Multifunctional Envelope-type Nanodevice for Use in Nanomedicine: Concept and Applications
Nakamura, T., Akita, H., Yamada, Y., Hatakeyama, H., & Harashima, H. (2012) · Accounts of Chemical Research · doi:10.1021/ar200254s · Cited by 88
CRISPR–Cas9 Genome Engineering in Saccharomyces cerevisiae CellsPreprint
Ryan, O. W., Poddar, S., & Cate, J. H. D. (2016) · Cold Spring Harbor Protocols · doi:10.1101/pdb.prot086827 · Cited by 87
Jarrett, K. E., Lee, C. M., Giorgi, M. D., Hurley, A. E., Gillard, B. K., Doerfler, A. M., Li, A., Pownall, H. J., Bao, G., & Lagor, W. R. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311221 · Cited by 87
Efficient and rapid generation of large genomic variants in rats and mice using CRISMERE
Birling, M., Schaeffer, L., André, P., Lindner, L., Maréchal, D., Ayadi, A., Sorg, T., Pavlovic, G., & Hérault, Y. (2017) · Scientific Reports · doi:10.1038/srep43331 · Cited by 86
Cas9-nickase–mediated genome editing corrects hereditary tyrosinemia in rats
Shao, Y., Wang, L., Guo, N., Wang, S., Yang, L., Li, Y., Wang, M., Yin, S., Han, H., Zeng, L., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000347 · Cited by 83
Gene Therapy for Chronic HBV—Can We Eliminate cccDNA?
Bloom, K. M., Maepa, M. B., Ely, A., & Arbuthnot, P. B. (2018) · Genes · doi:10.3390/genes9040207 · Cited by 82
Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1
Morrow, G., & Tanguay, R. M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55780-9_2 · Cited by 80
MORBIDITY AS A FOCUS OF PREVENTIVE HEALTH CARE IN THE ELDERLY
Fried, L. P., & Bush, T. L. (1988) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036028 · Cited by 79
Suresh (2017) · doi:10.1007/978-1-4939-6518-2_7 · Cited by 78
Seidah, N. G. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990313 · Cited by 77
Modeling human disease in rodents by CRISPR/Cas9 genome editing
Birling, M., Hérault, Y., & Pavlovic, G. (2017) · Mammalian Genome · doi:10.1007/s00335-017-9703-x · Cited by 77
Feng, W., Li, H., Xu, K., Chen, Y.-F., Pan, L., Mei, Y., Cai, H., Jiang, Y., Chen, T., & Feng, D.-X. (2016) · Gene · doi:10.1016/j.gene.2016.04.046 · Cited by 76
Zhou, Y., Han, C., Li, D., Yu, Z., Li, F., Li, F., An, Q., Bai, H., Zhang, X., Duan, Z., et al. (2015) · Scientific Reports · doi:10.1038/srep10433 · Cited by 74
Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system
Cheong, T.-C., Compagno, M., & Chiarle, R. (2016) · Nature Communications · doi:10.1038/ncomms10934 · Cited by 73
CRISPR/Cas9-mediated GJA8 knockout in rabbits recapitulates human congenital cataracts
Yuan, L., Sui, T., Chen, M., Deng, J., Huang, Y., Zeng, J., Lv, Q., Song, Y., Li, Z., & Lai, L. (2016) · Scientific Reports · doi:10.1038/srep22024 · Cited by 72
Efficient In Vivo Liver-Directed Gene Editing Using CRISPR/Cas9
Singh, K., Evens, H., Nair, N., Rincón, M. Y., Sarcar, S., Samara-Kuko, E., Chuah, M., & VandenDriessche, T. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.023 · Cited by 68
Bogerd, H. P., Kornepati, A. V. R., Marshall, J. B., Kennedy, E. M., & Cullen, B. R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516305112 · Cited by 66
CRISPR/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge
Lee, C.-H. (2019) · Molecules · doi:10.3390/molecules24071349 · Cited by 66
Tang, H., & Shrager, J. B. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506006 · Cited by 65
The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Alzheimer's Disease
Rohn, T. T., Kim, N., Isho, N. F., & Mack, J. M. (2018) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000439 · Cited by 64
Innovative Therapeutic Strategies for Cystic Fibrosis: Moving Forward to CRISPR Technique
Marangi, M., & Pistritto, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00396 · Cited by 61
Negative Feedback Regulation of HIV-1 by Gene Editing Strategy
Kaminski, R., Chen, Y., Salkind, J., Bella, R., Young, W., Ferrante, P., Karn, J., Malcolm, T., Hu, W., & Khalili, K. (2016) · Scientific Reports · doi:10.1038/srep31527 · Cited by 60
Wang, J., Chen, R., Zhang, R., Ding, S., Zhang, T., Yuan, Q., Guan, G., Chen, X., Zhang, T., Zhuang, H., et al. (2017) · Theranostics · doi:10.7150/thno.18114 · Cited by 58
Factors in the Genetic Background Suppress theEngrailed-1Cerebellar Phenotype
Bilovocky, N. A., Romito‐DiGiacomo, R. R., Murcia, C. L., Maricich, S. M., & Herrup, K. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-12-05105.2003 · Cited by 53
Variability in Genome Editing Outcomes: Challenges for Research Reproducibility and Clinical Safety
Teboul, L., Hérault, Y., Wells, S. E., Qasim, W., & Pavlovic, G. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.03.015 · Cited by 53
CRISPR/Cas9 Inhibits Multiple Steps of HIV-1 Infection
Yin, L., Hu, S., Mei, S., Sun, H., Xu, F., Li, J., Zhu, W., Liu, X., Zhao, F., Zhang, D., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.018 · Cited by 52
CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges
Demirci, S., Leonard, A., Haro-Mora, J. J., Uchida, N., & Tisdale, J. F. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2018_331 · Cited by 50
Addressing reproducibility in single-laboratory phenotyping experiments
Kafkafi, N., Golani, I., Jaljuli, I., Morgan, H., Sarig, T., Würbel, H., Yaacoby, S., & Benjamini, Y. (2017) · Nature Methods · doi:10.1038/nmeth.4259 · Cited by 48
Cystic fibrosis – an example of personalized and precision medicine
Skov, M., Hansen, C. R., & Pressler, T. (2019) · Apmis · doi:10.1111/apm.12915 · Cited by 44
Cai, Z., Zhang, X.-J., & Liu, Y. (2015) · Asian Journal of Andrology · doi:10.4103/1008-682x.157399 · Cited by 43
Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1
VanLith, C. J., Guthman, R. M., Nicolas, C. T., Allen, K. L., Du, Z., Joo, D. J., Nyberg, S. L., Lillegard, J. B., & Hickey, R. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.252 · Cited by 41
CRISPR/Cas9 Targeted Gene Editing and Cellular Engineering in Fanconi Anemia
Osborn, M. J., Lonetree, C.-L., Webber, B. R., Patel, D., Dunmire, S. K., DeFeo, A. P., McElroy, A. N., MacMillan, M. L., Wagner, J. E., Blazar, B. R., et al. (2016) · Stem Cells and Development · doi:10.1089/scd.2016.0149 · Cited by 39
HBV cccDNA and Its Potential as a Therapeutic Target
Zhu, A., Liao, X., Li, S., Zhao, H., Chen, L., Xu, M., & Duan, X. (2019) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2018.00054 · Cited by 39
Shah, S., Alexaki, A., Pirrone, V., Dahiya, S., Nonnemacher, M. R., & Wigdahl, B. L. (2014) · Virology Journal · doi:10.1186/1743-422x-11-92 · Cited by 36
Use of genome-editing tools to treat sickle cell disease
Tasan, I., Jain, S., & Zhao, H. (2016) · Human Genetics · doi:10.1007/s00439-016-1688-0 · Cited by 36
Upregulation of KLHDC4 Predicts a Poor Prognosis in Human Nasopharyngeal Carcinoma
Lian, Y., Yuan, J., Cui, Q., Feng, Q.-S., Xu, M., Bei, J., Zeng, Y.-X., & Feng, L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152820 · Cited by 35
CRISPR for Neuromuscular Disorders: Gene Editing and Beyond
Young, C. S., Pyle, A. D., & Spencer, M. J. (2019) · Physiology · doi:10.1152/physiol.00012.2019 · Cited by 35
Editing of the human TRIM5 gene to introduce mutations with the potential to inhibit HIV-1
Dufour, C., Claudel, A., Joubarne, N., Mérindol, N., Maisonnet, T., Masroori, N., Plourde, M. B., & Berthoux, L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191709 · Cited by 34
Wen, J., Tao, W., Hao, S., & Zu, Y. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0489-9 · Cited by 32
Janus kinase-3 dependent inflammatory responses in allergic asthma
Malaviya, R., Laskin, D. L., & Malaviya, R. (2010) · International Immunopharmacology · doi:10.1016/j.intimp.2010.04.014 · Cited by 29
CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells
Kramarzová, K. Š., Osborn, M. J., Webber, B. R., DeFeo, A. P., McElroy, A. N., Kim, C. A., & Tolar, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061269 · Cited by 29
Berardo, C., Siciliano, V., Pasqua, L. G. D., Richelmi, P., Vairetti, M., & Ferrigno, A. (2019) · European Journal of Histochemistry · doi:10.4081/ejh.2019.3048 · Cited by 28
Muenzer, J., Prada, C. E., Burton, B. K., Lau, H., Ficicioglu, C. H., Foo, C. W. P., Vaidya, S. A., Whitley, C. B., & Harmatz, P. (2019) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2018.12.263 · Cited by 27
A large CRISPR-induced bystander mutation causes immune dysregulation
Simeonov, D. R., Brandt, A. J., Chan, A. Y. K., Cortez, J. T., Li, Z., Woo, J. M., Lee, Y., Carvalho, C. M. B., Indart, A. C., Roth, T. L., et al. (2019) · Communications Biology · doi:10.1038/s42003-019-0321-x · Cited by 24
VISUAL IMPAIRMENT IN RETINITIS PIGMENTOSA
Vezinaw, C. M., Fishman, G. A., & McAnany, J. J. (2019) · Retina · doi:10.1097/iae.0000000000002649 · Cited by 23
Genome-Wide CRISPR/Cas9 Screening for High-Throughput Functional Genomics in Human Cells
Zhu, S., Zhou, Y., & Wei, W. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7237-1_11 · Cited by 20
Al-Ateeq, S., Ovchinnikov, D. A., Tracey, T. J., Whitworth, D. J., Al‐Rubaish, A. M., Al‐Ali, A. K., & Wolvetang, E. J. (2018) · APL Bioengineering · doi:10.1063/1.5048625 · Cited by 18
Rose, B. I., & Brown, S. (2019) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000003327 · Cited by 17
Transfection of Difficult-to-Transfect Rat Primary Cortical Neurons with Magnetic Nanoparticles
Jin, W.-Y., Lin, D., Anh, N. T. V., et al. (2018) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2018.2604 · Cited by 15
Cited by
Kenjo, E., Hozumi, H., Makita, Y., Iwabuchi, K. A., Fujimoto, N., Matsumoto, S., Kimura, M., Amano, Y., Ifuku, M., Naoe, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26714-w · Cited by 300
N6-methyladenosine methyltransferases: functions, regulation, and clinical potential
Huang, W., Chen, T.-Q., Fang, K., Zeng, Z.-C., Ye, H., & Chen, Y.-Q. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01129-8 · Cited by 275
RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential
Qu, J., Yan, H., Hou, Y., Cao, W., Liu, Y., Zhang, E., He, J., & Cai, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01224-4 · Cited by 260
Strategies to enhance CAR-T persistence
Liu, Y., An, L., Huang, R., Xiong, J., Yang, H., Wang, X., & Zhang, X. (2022) · Biomarker Research · doi:10.1186/s40364-022-00434-9 · Cited by 97
New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing
Oostveen, R. F., Khera, A. V., Kathiresan, S., Stroes, E. S. G., Fitzgerald, K., Harms, M. J., Oakes, B. L., & Kastelein, J. J. P. (2023) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.122.317963 · Cited by 31
Metadata
- Authors
- Sharma, G., Sharma, A. R., Bhattacharya, M., Lee, S.-S., & Chakraborty, C.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 29
- Issue
- 2
- Pages
- 571-586
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W3088253143
- Cited by
- 283
- References
- 202
- FWCI
- 8.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.